Literature DB >> 24573106

Current concepts in psoriatic arthritis: pathogenesis and management.

Kurt de Vlam1, Alice B Gottlieb, Philip J Mease.   

Abstract

Psoriatic arthritis occurs in a subset of psoriasis patients and is therefore commonly encountered in dermatology practice. Although its exact pathogenesis is unknown, psoriatic arthritis is thought to share common mechanisms with psoriatic skin symptoms. Innate and adaptive immune responses are abnormally activated in psoriasis and may acquire the ability to attack peripheral joints and other sites following an environmental trigger (e.g. mechanical stress, trauma, infection) in genetically susceptible patients. The increased cardiovascular risk inherent in psoriasis appears further enhanced in psoriatic arthritis, likely reflecting the overall burden of systemic inflammation contributing to atherogenic processes. Basic research and clinical trials have suggested that tumour necrosis factor is important in psoriatic arthritis pathophysiology, and accumulating evidence suggests that Th17 cells and interleukin-17A may also be important. Basic research and clinical trials inform our understanding of psoriatic arthritis pathophysiology and, in turn, help dermatologists to make better treatment decisions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24573106     DOI: 10.2340/00015555-1833

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  20 in total

Review 1.  Secukinumab: a promising therapeutic option in spondyloarthritis.

Authors:  Hernan Maldonado-Ficco; Rodolfo Perez-Alamino; José A Maldonado-Cocco
Journal:  Clin Rheumatol       Date:  2016-07-20       Impact factor: 2.980

2.  A marine fungus-derived nitrobenzoyl sesquiterpenoid suppresses receptor activator of NF-κB ligand-induced osteoclastogenesis and inflammatory bone destruction.

Authors:  Yanhui Tan; Wende Deng; Yueyang Zhang; Minhong Ke; Binhua Zou; Xiaowei Luo; Jianbin Su; Yiyuan Wang; Jialan Xu; Kutty Selva Nandakumar; Yonghong Liu; Xuefeng Zhou; Xiaojuan Li
Journal:  Br J Pharmacol       Date:  2020-08-11       Impact factor: 8.739

Review 3.  Tumor necrosis factor inhibitors in psoriatic arthritis.

Authors:  Santhi Mantravadi; Alexis Ogdie; Walter K Kraft
Journal:  Expert Rev Clin Pharmacol       Date:  2017-05-22       Impact factor: 5.045

Review 4.  Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?

Authors:  Philippa D K Curry; Andrew P Morris; Anne Barton; James Bluett
Journal:  Pharmacogenomics J       Date:  2022-10-15       Impact factor: 3.245

5.  Epidemiology and clinical characteristics of psoriatic arthritis-related uveitis in Madrid, Spain.

Authors:  Víctor Aguado Casanova; Beatriz Ventas; Jaime Arroyo Palomo; Fernando J Huelin Alcubierre; Lourdes Villalobos Sánchez; Marcelino Revenga Martínez; Julio J Gonzalez-Lopez
Journal:  Int Ophthalmol       Date:  2022-08-30       Impact factor: 2.029

Review 6.  Recent advances in understanding and managing psoriatic arthritis.

Authors:  Dafna D Gladman
Journal:  F1000Res       Date:  2016-11-16

7.  Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.

Authors:  Philip J Mease; Désirée van der Heijde; Christopher T Ritchlin; Masato Okada; Raquel S Cuchacovich; Catherine L Shuler; Chen-Yen Lin; Daniel K Braun; Chin H Lee; Dafna D Gladman
Journal:  Ann Rheum Dis       Date:  2016-08-23       Impact factor: 19.103

8.  Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1.

Authors:  Laura C Coates; Mitsumasa Kishimoto; Alice Gottlieb; Catherine L Shuler; Chen-Yen Lin; Chin Hyok Lee; Philip J Mease
Journal:  RMD Open       Date:  2017-12-22

9.  Hypothesis-free analyses from a large psoriatic arthritis cohort support merger to consolidated peripheral arthritis definition without subtyping.

Authors:  Daniel Stekhoven; Almut Scherer; Michael J Nissen; Véronique Grobéty; Nikhil Yawalkar; Peter M Villiger; Burkhard Möller
Journal:  Clin Rheumatol       Date:  2017-04-22       Impact factor: 2.980

10.  Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases.

Authors:  Morten L Halling; Jens Kjeldsen; Torben Knudsen; Jan Nielsen; Lars Koch Hansen
Journal:  World J Gastroenterol       Date:  2017-09-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.